Selling an AI feature into an Epic-using hospital is a structured 6–18 month process spanning stakeholder mapping (CMIO, CISO, IT leadership, specialty clinical leadership, procurement, legal/compliance), clinical-safety review (eval methodology, gold-standard validation, override patterns, deployment scope), security review (BAA paper trail, encryption, audit logging, penetration testing, vulnerability scanning), Epic technical review (SMART on FHIR architecture, App Orchard certification status, FHIR scope analysis, integration impact assessment), procurement and contracting (Master Services Agreement, BAA, statements of work, IT-purchasing review), and clinical pilot (defined cohort, change management, measurement methodology, post-pilot rollout decision). Most healthtech vendors that fail to land Epic hospital deployments fail at one of these stages because they were treating it as a sales process rather than a structured operational engagement. The hospitals that move fastest are the ones whose vendors arrive prepared with the artifacts every stage requires; vendors who improvise at each stage typically lose 6–12 months of deployment time relative to vendors who arrive with the structured engagement ready.
Selling an AI feature into a hospital is one of the most operationally complex go-to-market motions in healthcare. The procurement cycle is long, the stakeholder count is high, the technical requirements are deep, and the clinical-safety bar is non-trivial. Healthtech vendors who treat the process as a traditional B2B sale produce 18–24 month sales cycles with high failure rates; vendors who treat it as a structured operational engagement produce 6–12 month deployment cycles with much higher landing rates.
This guide is the operational reference Taction Software® uses with healthtech founders and AI vendor leadership going to market with Epic-targeted features. It applies similarly (with EHR-specific variations) to Cerner-Oracle, Athena, and Allscripts deployments.
The Six Stages of an Epic Hospital Deployment
The six stages — each with specific stakeholders, artifacts, and exit criteria.
Stage 1 — Stakeholder Mapping (Weeks 1–4)
Identify the relevant stakeholders at the target hospital. The decision is rarely a single buyer; it’s a multi-stakeholder review.
Key stakeholders.
- CMIO (Chief Medical Information Officer) — clinical champion, usually the executive sponsor for AI features. Cares about clinical workflow fit, accuracy, override patterns, clinician adoption.
- CISO (Chief Information Security Officer) — security gate. Cares about BAA paper trail, encryption, audit logging, breach response, vulnerability management.
- Director of IT / VP of IT — technical architecture review. Cares about Epic integration depth, App Orchard status, infrastructure compatibility, ongoing operational impact.
- Specialty clinical leadership — the clinical champions for the use case (head of ED, head of cardiology, head of oncology, etc.). Cares about specialty workflow fit, clinical accuracy, override patterns.
- Procurement / Supply Chain — contracting gate. Cares about contract terms, vendor financial stability, references.
- Legal / Compliance — BAA review, contract terms, regulatory considerations. Cares about HIPAA scope, FDA SaMD positioning, indemnification.
Artifacts produced at this stage.
- Stakeholder map with names, roles, decision authority, and concerns
- Initial outreach plan
- Discovery-conversation prep materials per stakeholder
Stage 2 — Discovery and Initial Demo (Weeks 4–10)
Discovery conversations with each stakeholder. Initial demo to the CMIO and clinical champion. Initial security and architecture review with the CISO and IT leadership.
Outcomes.
- Clinical champion alignment on use case fit and workflow integration
- CISO initial alignment on security posture (no fatal gaps)
- IT leadership initial alignment on architecture (no fatal gaps)
- Clinical leadership engagement for the specific specialty
Artifacts produced at this stage.
- Demo recording or live demo
- Initial security questionnaire response
- Initial architecture review document
- Pilot scope proposal
Stage 3 — Security Review and BAA Negotiation (Weeks 10–20)
The deep security review. The CISO’s team runs detailed evaluation:
- Penetration testing (or accepts a third-party pen-test report)
- Vulnerability scanning (continuous monitoring of the vendor’s deployed infrastructure)
- BAA review and negotiation
- Sub-processor list review
- Audit-logging review against the institution’s compliance requirements
- Breach-response plan review
- Encryption posture (at rest, in transit, key management)
Outcomes.
- Signed BAA between the hospital and the AI vendor
- Security posture documented and approved
- Vulnerability and pen-test findings remediated
Artifacts produced at this stage.
- Signed BAA
- SOC 2 Type II report (the hospital expects this)
- Pen-test report (with remediations of findings)
- Security architecture document
Stage 4 — Clinical-Safety Review and Eval Validation (Weeks 14–22)
Parallel to security review. The clinical-safety review evaluates:
- Eval methodology (test set construction, gold-standard adjudication, statistical methodology)
- Performance metrics (accuracy, sensitivity, specificity, calibration, subgroup performance)
- Override patterns (how the AI’s output is reviewed and what happens when clinicians disagree)
- Hallucination risk (how the architecture prevents fabricated clinical claims)
- Failure modes and clinical-safety mitigations
- Deployment scope and pilot population definition
Outcomes.
- Clinical-safety committee approval for pilot deployment
- Pilot population defined
- Pilot success metrics agreed
- Pilot timeline committed
Artifacts produced at this stage.
- Clinical-safety review document
- Eval results presentation
- Pilot protocol document
Stage 5 — Epic Technical Integration (Weeks 18–32)
Parallel to clinical-safety review. The Epic technical integration includes:
- SMART on FHIR launch context configuration
- FHIR scope confirmation and approval
- App Orchard certification status (or confirmation of progress)
- Integration testing against the hospital’s specific Epic environment
- Performance and load testing
- Failover and resilience testing
Outcomes.
- Production Epic integration deployed in non-clinical environment
- App Orchard certification (where applicable)
- Performance benchmarks meeting institutional targets
- Failure-mode behavior validated
Artifacts produced at this stage.
- Integration test results
- App Orchard certification (where applicable)
- Production architecture document
Stage 6 — Pilot Deployment and Rollout Decision (Weeks 24–48)
The pilot runs in production with the defined cohort, the agreed measurement methodology, and the change-management infrastructure in place. Pilot duration is typically 12–16 weeks.
Outcomes at pilot completion.
- Adoption rate measured
- Clinical outcome metrics measured
- Override patterns analyzed
- Clinician feedback aggregated
- Operational incident rate documented
The post-pilot decision.
- Scale to broader rollout — pilot exceeded thresholds; rollout to additional cohorts/specialties/sites
- Iterate further — pilot was promising but specific gaps need addressing before broader rollout
- Don’t proceed — pilot didn’t meet thresholds; the deployment ends
What Vendors Typically Get Wrong
Five patterns that produce extended sales cycles or failed landings.
Mistake 1 — Treating It as Traditional B2B Sales
A vendor approaches the hospital with sales-style outreach (lead-gen, demo-focused, pricing-pitch). The clinical and IT stakeholders don’t engage; the CMIO doesn’t see why this is differentiated; security review doesn’t start because the vendor hasn’t engaged the CISO. Resolution: structured operational engagement from the start — every stage has artifacts the hospital expects.
Mistake 2 — Arriving Without Security Artifacts
A vendor pitches the AI feature, gets clinical interest, then can’t produce the SOC 2 report, pen-test report, or detailed BAA the security review requires. The deal stalls 8+ weeks while the vendor scrambles to produce them. Resolution: security artifacts are produced before going to market, not after a pitch lands.
Mistake 3 — Underestimating Eval Methodology Bar
A vendor presents accuracy claims with weak methodology — single-reviewer gold standards, retrospective-only evaluation, no subgroup performance reporting. The clinical-safety review rejects the claims. Resolution: eval methodology meets institutional standards from week 1 of vendor product development.
Mistake 4 — No Pilot Scope Clarity
A vendor proposes a pilot but can’t define population, success metrics, or timeline crisply. The clinical-safety committee can’t approve an undefined deployment. Resolution: pilot scope is part of the pre-pitch preparation, not a post-interest deliverable.
Mistake 5 — Treating Each Hospital as a Custom Engagement
A vendor sells the second hospital with the same custom-engagement structure as the first. Sales cycles are long; the vendor never produces a repeatable motion. Resolution: the second hospital deployment is structurally similar to the first; productized go-to-market structures (pre-built artifacts, repeatable pilot protocols, standard contracting templates) compress the cycle materially.
What Hospitals Typically Want to See
The artifacts hospitals expect AI vendors to bring to the engagement. Vendors who arrive with these artifacts move 4–6x faster through the process than vendors who produce them on demand.
- SOC 2 Type II report
- HIPAA Security Risk Analysis (per §164.308(a)(1)(ii)(A))
- BAA template
- Architecture diagram with PHI flow map
- Penetration test report (within last 12 months)
- Sub-processor list with BAA coverage status
- Eval methodology document
- Clinical accuracy metrics with subgroup performance
- Pilot protocol template
- Sample pilot success-metric definitions
- Reference customers with similar use cases (where available)
- App Orchard / Code Console / athenaOne marketplace certification status
- Pricing structure (transparent, productized where possible)
The Repeatable Go-to-Market Motion
The structure that produces second and third deployments much faster than the first.
Pre-built artifact library. SOC 2, pen-test, BAA template, architecture diagram, eval methodology, pilot protocol, etc. — produced once, used across many engagements.
Productized engagement structure. $45K Discovery / $95K MVP / $145K Pilot-Ready — pricing the hospital can review and approve through standard procurement without custom-quote negotiation.
Reference customer development. The first hospital is a reference for the second. The second for the third. Building reference customers explicitly is part of the go-to-market motion, not an organic happening.
Specialist partner relationships. For technical and operational scope outside the AI vendor’s core (Epic-specific deep integration, federal compliance, etc.), specialist partner relationships compress the engagement. The vendor doesn’t have to internalize every capability.
Closing
Selling AI features into Epic hospitals in 2026 is a structured operational engagement, not a traditional B2B sale. The six stages are well-defined; the artifacts each stage requires are well-understood; the timelines are predictable. Vendors who arrive with the structured engagement produce 6–12 month deployment cycles. Vendors who improvise produce 18–24 month cycles or fail to land.
The artifact library and productized engagement structure compound advantage across deployments. Build them once; deploy them across many hospitals.
If you are a healthtech vendor going to market with an Epic-targeted AI feature and want a partner who handles the engineering and certification scope while you focus on commercial execution, book a 60-minute scoping call. Taction Software has shipped 200+ EHR integrations across Epic, Cerner-Oracle, Athena, and Allscripts since 2013, with active App Orchard, Cerner Code Console, athenaOne marketplace, and Allscripts ADP relationships. Zero HIPAA findings on shipped software, and active BAA paper trails with every major AI provider. Our healthcare engineering team handles the engineering, certification, and security artifact production that hospital deployments require. Our verified case studies cover the production deployments behind these patterns. For the engineering scope behind the engagement, see our healthcare software development practice and our hospital and health-system practice for the operational context. For the FHIR API patterns this work depends on, see our healthcare data integration practice and our broader FHIR API development work. For an estimate against your specific use case, see the healthcare engineering cost calculator. For deeper context on the AI features this work supports, see our broader generative AI healthcare applications work.